Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients

RG7667, a novel combination of two anticytomegalovirus (anti-CMV) monoclonal IgG1 antibodies (MCMV5322A and MCMV3068A), was designed to block CMV entry into host cells. It was developed as a potential therapy for preventing CMV infection and disease in transplant recipients. RG7667 was assessed for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Deng, Rong, Wang, Yehong, Maia, Mauricio, Burgess, Tracy, McBride, Jacqueline M., Liao, X. Charlene, Tavel, Jorge A., Hanley, William D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2018
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5786805/
https://ncbi.nlm.nih.gov/pubmed/29133549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01108-17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados